Stockscreener 앱 받기
44.63
2.15%
-0.98
시간 외 거래:
44.21
-0.42
-0.94%
전일 마감가:
$45.61
열려 있는:
$45.19
하루 거래량:
572.07K
Relative Volume:
0.77
시가총액:
$2.59B
수익:
$776.83M
순이익/손실:
$-29.02M
주가수익비율:
-87.17
EPS:
-0.512
순현금흐름:
$82.25M
1주 성능:
-3.40%
1개월 성능:
-4.04%
6개월 성능:
-7.33%
1년 성능:
+27.15%
1일 변동 폭
$44.35
$45.67
1주일 범위
$44.35
$48.45
52주 변동 폭
$34.64
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
명칭
Supernus Pharmaceuticals Inc
전화
301-838-2500
주소
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
44.63 | 2.73B | 776.83M | -29.02M | 82.25M | -0.512 |
TAK
Takeda Pharmaceutical Co Adr
|
17.10 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.855 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.01 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.28 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
517.71 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-09 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-09-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | 재개 | Jefferies | Buy |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-04-13 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-06-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | 재개 | Jefferies | Hold |
| 2019-11-08 | 다운그레이드 | Berenberg | Buy → Hold |
| 2019-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-11-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-11-12 | 재확인 | B. Riley FBR | Buy |
| 2018-01-18 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-08 | 업그레이드 | Stifel | Hold → Buy |
| 2017-10-19 | 개시 | FBR & Co. | Buy |
| 2017-09-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-07-17 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | 개시 | Janney | Neutral |
| 2017-06-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2015-11-05 | 재확인 | Northland Capital | Outperform |
| 2015-10-28 | 개시 | Northland Capital | Outperform |
모두보기
Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
Supernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo! Finance Canada
Supernus Pharmaceuticals, Inc. Revenue Breakdown – GETTEX:S49 - TradingView
Is Rising Earnings Optimism Altering The Investment Case For Supernus Pharmaceuticals (SUPN)? - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Could Be 25% Undervalued On Rising Earnings Expectations - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Supernus Pharmaceuticals Inc - TradingKey
SUPN|Supernus Pharmaceuticals Inc|Price:47.000|Chg%:+0.800 - TradingKey
Supernus Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:SUPN - TradingView
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales? - TradingView
Supernus Pharmaceuticals Inc (SUPN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Supernus Pharmaceuticals to announce Q2 2026 results on August 4 - scanx.trade
Supernus Pharmaceuticals to Announce Q2 2026 Financial Results and Host Investor Conference Call on August 4, 2026 1 – Minichart - Minichart
Supernus Pharmaceuticals to Announce Q2 2026 Earnings and Host Conference Call on August 4 - Kalkine Media
Supernus to Report Q2 2026 Results, Conference Call Scheduled for August 4 - TradingView
Supernus Pharmaceuticals to Announce Second Quarter 2026 - GlobeNewswire
Supernus Pharmaceuticals (SUPN) Could Be 24% Undervalued If Its CNS Pipeline Delivers - Sahm
Avoiding Lag: Real-Time Signals in (SUPN) Movement - Stock Traders Daily
Jack Khattar: Innovator, Business Leader, and Founder, President and CEO of Supernus Pharmaceuticals - BBN Times
Supernus Pharmaceuticals, Inc. (SUPN) Investor Outlook: A 33.91% Upside Potential Amid Strong Revenue Growth - DirectorsTalk Interviews
ETFs Investing in Supernus Pharmaceuticals, Inc. Stocks - TradingView
Supernus Pharmaceuticals (SUPN) Holds Near Support Amid Steady TradingUp Down Volume - dars.gov.et
Supernus marks five years since Qelbree ADHD drug approval By Investing.com - Investing.com Nigeria
Supernus marks five years since Qelbree ADHD drug approval - Investing.com
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD - The Manila Times
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA - GlobeNewswire
BofA Securities Initiates Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Announces Target Price $63 - Moomoo
SUPN Maintained by Cantor Fitzgerald -- Price Target Raised to $67.00 - GuruFocus
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength? - Yahoo Finance
Britannia, US WorldMeds, Supernus move for judgment in US antitrust case on Apokyn - MLex
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – BX:S49 - TradingView
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – DUS:S49 - TradingView
Price to sales forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Supernus Pharmaceuticals (SUPN) Following Shelf Filing Has Its Undervalued Case In Focus - Sahm
Price to sales forward of Supernus Pharmaceuticals, Inc. – FWB:S49 - TradingView
Discipline and Rules-Based Execution in SUPN Response - Stock Traders Daily
SUPN Q1 2026 Earnings: EPS Surges 97.69% Above EstimatesEarnings Sentiment Score - dars.gov.et
Price to book forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Enterprise value to EBIT forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Enterprise value to EBIT forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView
Q3 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Supernus Pharmaceuticals, Inc. Actuals & Estimates (BX:S49) - TradingView
Price to earnings forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Supernus Pharmaceuticals, Inc. Actuals & Estimates (LSE:0LB2) - TradingView
S49 Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView
SUPN Forecast — Price Target — Prediction for 2027 - TradingView
Supernus Pharmaceuticals, Inc. Actuals & Estimates (LSX:A1JX3U) - TradingView
0LB2 Forecast — Price Target — Prediction for 2027 - TradingView
A1JX3U Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView
Supernus Pharmaceuticals Inc (SUPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Supernus Pharmaceuticals Inc 주식 (SUPN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Option Exercise |
33.62 |
50,000 |
1,681,205 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Option Exercise |
39.40 |
7,250 |
285,650 |
24,294 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Sale |
50.30 |
50,000 |
2,514,886 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Sale |
50.28 |
50,000 |
2,513,925 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Sale |
49.60 |
7,250 |
359,621 |
17,044 |
2.08%
0.17%
자본화:
|
볼륨(24시간):